Total sales for cardiovascular diseases will grow steadily over the next six years, reaching about $60B in 2023.

The top five major drivers of this growth will be two anticoagulants (Bristol-Myers Squibb’s [BMS’] Eliquis [apixaban]‎ and Johnson & Johnson [J&J]/Bayer’s Xarelto [rivaroxaban]), a heart failure drug (Novartis’s Entresto [sacubitril/valsartan]) and two drugs for pulmonary arterial hypertension (J&J’s Opsumit [macitentan] and Uptravi [selexipag]). These five drugs will represent 50% of the total cardiovascular market in 2023, while Eliquis and Xarelto alone will represent 36% of the whole cardiovascular market. Cholesterol-lowering drugs were not part of this analysis, as they were considered to be part of the metabolic disorders therapeutic area.

The rest of the cardiovascular market, excluding the aforementioned five drugs, will not experience a significant growth over the coming years. This is mainly due to the fact that this market is very mature and heavily genericized, and therefore difficult to penetrate. However, this whole space is replete with unmet needs as most of the cardiovascular conditions are incurable. Thus, there still remains a huge opportunity for drug developers to tap into this potentially lucrative market with innovative and ideally disease-modifying therapies.

Currently, many companies are hesitant to invest into this market due to a low return on investment. However, as exemplified by Eliquis, Xarelto, and Entresto, all of which penetrated heavily generic spaces, targeting the right patient populations with high unmet needs can be exceptionally profitable.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.